Spironolactone pharmacokinetics and pharmacodynamics in cirrhotics with ascites
Read Online
Share

Spironolactone pharmacokinetics and pharmacodynamics in cirrhotics with ascites

  • 983 Want to read
  • ·
  • 58 Currently reading

Published by National Library of Canada in Ottawa .
Written in English


Book details:

Edition Notes

SeriesCanadian theses = Thèses canadiennes
The Physical Object
FormatMicroform
Pagination3 microfiches.
ID Numbers
Open LibraryOL18682715M
ISBN 100315565861
OCLC/WorldCa24907130

Download Spironolactone pharmacokinetics and pharmacodynamics in cirrhotics with ascites

PDF EPUB FB2 MOBI RTF

The intent of this study was to identify pharmacokinetic and pharmacodynamic characteristics for spironolactone (SP) and its metabolites (canrenone, 6β-hydroxy-7α-thiomethylspirolactone, 7α-thiomethylspirolactone) in cirrhotics under steady state conditions. Nine cirrhotics with ascites participated in the study. Serial blood samples were drawn and urine was collected over a hour Cited by: Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Sungaila I(1), Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E. Author information: (1)Department of Pharmacy, Sunnybrook Health Science Centre, Toronto, by: The intent of this study was to identify pharmacokinetic and pharmacodynamic characteristics for spironolactone (SP) and its metabolites (canrenone, 6β-hydroxy-7α-thiomethylspirolactone, 7α-thiomethylspirolactone) in cirrhotics under steady state conditions. Nine cirrhotics with ascites participated in the by: Spironolacotone and eplerenone are mineralocorticoid-blocking agents used for their ability to block both the epithelial and non-epithelial actions of aldosterone. Spironolactone is a non-selective mineralocorticoid receptor antagonist with moderate affinity for both progesterone and androgen receptors. The latter property increases the likelihood of endocrine side effects with spironolactone.

The pharmacodynamics of spironolactone, an antimineralocorticoid and antiandrogen medication, concern its mechanisms of action, including its biological targets and activities, as well as its physiological pharmacodynamics of spironolactone are characterized by high antimineralocorticoid activity, moderate antiandrogenic activity, and weak steroidogenesis inhibition. Refractory ascites (or diuretic-resistant ascites), i.e. ascites that cannot be mobilized by medical treatment (low sodium diet and high doses of furosemide and spironolactone) is an infrequent phenomenon in cirrhosis. It usually occurs in patients with functional renal failure as a consequence of alteration in both pharmacokinetics and. Spironolactone, sold under the brand name Aldactone among others, is a medication that is primarily used to treat fluid build-up due to heart failure, liver scarring, or kidney disease. It is also used in the treatment of high blood pressure, low blood potassium that does not improve with supplementation, early puberty in boys, acne and excessive hair growth in women, and as a part of.   Free Online Library: Pharmacokinetic study of frusemide in healthy and cirrhotic Indian subjects.(Original Work, Clinical report) by "Internet Journal of Medical Update"; Health, general Furosemide Dosage and administration Health aspects Liver cirrhosis Development and progression Drug therapy Pharmacokinetics Research.

Since spironolactone and triamterene are primarily metabolized by the liver, reduced dosages of these drugs may also be necessary in severe hepatic impairment. References Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, Vidins E "Spironolactone pharmacokinetics and pharmacodynamics in patis with cirrhotic ascites.". It usually occurs in patients with functional renal failure as a consequence of alterations in both pharmacokinetics and pharmacodynamics of diuretics. Peritoneo-venous shunting, a procedure which improves systemic haemodynamics and renal function in cirrhotics with ascites, has been proposed as the treatment of choice in patients with. Aldactone has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions). Aldactone should be used only in those conditions described under Indications and Usage. Unnecessary use of this drug should be avoided. DESCRIPTION Aldactone oral tablets contain 25 mg, 50 mg, or mg of the aldosterone antagonist spironolactone. Equimolar doses of spironolactone (I), canrenone (II) and canrenoate-K (III) were given orally and III intravenously to 16 patients. Canrenoate-K (III) was rapidly and quantitatively absorbed from the gastrointestinal tract and bypassed the liver unchanged. The oral bioavailability of the lipophilic II to the central compartment was about 80% relative to III in one patient, which was.